Resmed (RMD) Stock News

Macquarie says ResMed's reiterated annual revenue guidance of US$5.75-5.85 billion implies a slight operational upgrade, given increased currency headwinds. The bank keeps outperform and lifts its target price 1.5% to A$47.50. Shares are down 7.2% at A$32.96.

Macquarie lifted its price target on ResMed to A$47.50 per share, up 1.5%. The adjustment reflects a modest revision in the bank's valuation view.

Barrenjoey lifted its ResMed price target to A$37.50 per share, up 3.6%. The move reflects a modest upward revision in the broker's view, though no supporting rationale was disclosed.

ResMed shares fall 9.1% in broad market selloff, volume nearly triples.

ResMed backed its FY27 adjusted EPS guidance of $12.00-$12.25 per share, following a Q1 earnings beat that included revenue and EPS above consensus.

Resmed reported Q1 revenue of $1.415B, up 6% YoY, and GAAP EPS of $2.92, up 23%. Non-GAAP EPS rose 14% to $2.91. The company also declared a quarterly dividend of $0.66 per share.

Morgan Stanley increased its price target for ResMed by 3.6%.